Sanara Medtech Inc. (SMTI) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Sanara Medtech Inc. is a medical technology company operating through two reportable segments: Sanara Surgical (soft tissue repair and bone fusion products) and Tissue Health Plus (THP) (value-based wound care services). The company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $25.83 million | $49.26 million | $20.16 million | $38.70 million |
| Gross Profit | $23.89 million | $45.49 million | $18.15 million | $34.80 million |
| Gross Margin | 92.5% | 92.3% | 90.0% | 90.0% |
| Net Loss | $(2.02) million | $(5.55) million | $(3.53) million | $(5.33) million |
| Net Loss Per Share (Basic/Diluted) | $(0.23) | $(0.64) | $(0.41) | $(0.62) |
| Operating Cash Flow (YTD) | $0.67 million | $(3.01) million | N/A | N/A |
| Cash and Equivalents (End of Period) | $16.96 million | N/A | N/A | N/A |
| Long-Term Debt (Net) | $44.22 million | N/A | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 28% year-over-year in Q2 and 27% year-over-year YTD, driven by increased sales of soft tissue repair products (CellerateRX Surgical, BIASURGE) and bone fusion products due to market penetration and geographic expansion.
- Profitability: While the company reported a net loss, the loss narrowed significantly in Q2 2025 compared to Q2 2024 (from $3.53M to $2.02M). Segment Adjusted EBITDA improved to $2.66 million in Q2 2025 from $0.59 million in Q2 2024.
- Debt Expansion: Long-term debt increased from $30.69 million at year-end 2024 to $44.22 million at June 30, 2025. This reflects a "Third Borrowing" of $12.25 million under the CRG Term Loan in March 2025.
- Investing Activity: Significant cash outflows in investing activities ($9.1 million YTD) were driven by the CarePICS acquisition ($2.1 million), investment in BMI ($3.5 million), and capitalization of THP technology platform costs ($3.4 million).
Guidance, Outlook, and Risks
- THP Strategy: The company launched its first THP pilot program in Q2 2025. Management projects cash investment in THP for the second half of 2025 to be between $5.5 million and $6.5 million. No material cash investments are anticipated after year-end.
- Debt Covenants: The CRG Term Loan requires maintaining annual minimum revenue of $75.0 million for the 2025 fiscal year. As of June 30, 2025, the company is in compliance with all debt covenants.
- Acquisitions & Investments:
- CarePICS: Acquired in April 2025 to support the THP platform. Includes potential earnout payments up to $10 million based on SaaS P&L EBITDA and patient volume.
- BMI: Acquired exclusive U.S. distribution rights for OsStic and ARC. Agreed to contribute up to an additional €4.0 million upon milestone achievement. Two milestones were achieved in June 2025, triggering a $2.4 million payment in July 2025.
- Risks: Key risks include the ability to meet future capital requirements, compliance with debt covenants, realization of benefits from acquisitions, and the success of the value-based wound care strategy.
Investor Verification Checklist
- Debt Capacity: Verify the remaining $12.25 million availability under the CRG Term Loan and the impact of the 13.25% interest rate (with 5.25% PIK option) on future cash flows.
- THP Cash Burn: Monitor the execution of the projected $5.5M–$6.5M H2 2025 investment in THP and the timeline for revenue generation from the pilot program.
- Revenue Covenants: Confirm the company's trajectory to meet the $75.0 million annual revenue covenant for 2025 to avoid default.
- Acquisition Milestones: Track the achievement of BMI milestones and the associated capital contribution obligations.
- Related Party Transactions: Review ongoing royalty payments and consulting fees to Rochal Industries and Catalyst, which are related parties.